These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
123 related articles for article (PubMed ID: 3285427)
1. [Buspirone: pharmacological and clinical properties of the first member of a new anxiolytic drug family]. Bonvalot T; Boulenger JP; Zarifian E Rev Med Interne; 1988; 9(1):97-103. PubMed ID: 3285427 [TBL] [Abstract][Full Text] [Related]
5. Buspirone, a new approach to the treatment of anxiety. Taylor DP FASEB J; 1988 Jun; 2(9):2445-52. PubMed ID: 2836252 [TBL] [Abstract][Full Text] [Related]
6. Buspirone: an update on a unique anxiolytic agent. Jann MW Pharmacotherapy; 1988; 8(2):100-16. PubMed ID: 3041384 [TBL] [Abstract][Full Text] [Related]
8. Azapirones: an alternative to benzodiazepines for anxiety. Cadieux RJ Am Fam Physician; 1996 May; 53(7):2349-53. PubMed ID: 8638511 [TBL] [Abstract][Full Text] [Related]
9. Imipramine and buspirone in treatment of patients with generalized anxiety disorder who are discontinuing long-term benzodiazepine therapy. Rickels K; DeMartinis N; García-España F; Greenblatt DJ; Mandos LA; Rynn M Am J Psychiatry; 2000 Dec; 157(12):1973-9. PubMed ID: 11097963 [TBL] [Abstract][Full Text] [Related]
10. Long-term anxiolytic therapy: the issue of drug withdrawal. Lader M J Clin Psychiatry; 1987 Dec; 48 Suppl():12-6. PubMed ID: 2891684 [TBL] [Abstract][Full Text] [Related]
11. Concentrations and effects of buspirone are considerably reduced by rifampicin. Lamberg TS; Kivistö KT; Neuvonen PJ Br J Clin Pharmacol; 1998 Apr; 45(4):381-5. PubMed ID: 9578186 [TBL] [Abstract][Full Text] [Related]
12. Distinguishing a benzodiazepine agonist (triazolam) from a nonagonist anxiolytic (buspirone) by electroencephalography: kinetic-dynamic studies. Greenblatt DJ; Harmatz JS; Gouthro TA; Locke J; Shader RI Clin Pharmacol Ther; 1994 Jul; 56(1):100-11. PubMed ID: 8033487 [TBL] [Abstract][Full Text] [Related]
13. Effect of the novel anxiolytic drug deramciclane on the pharmacokinetics and pharmacodynamics of the CYP3A4 probe drug buspirone. Laine K; Ahokoski O; Huupponen R; Hänninen J; Palovaara S; Ruuskanen J; Björklund H; Anttila M; Rouru J Eur J Clin Pharmacol; 2003 Dec; 59(10):761-6. PubMed ID: 14566442 [TBL] [Abstract][Full Text] [Related]
14. The new and newer antianxiety agents. Tiller JW Med J Aust; 1989 Dec 4-18; 151(11-12):697-701. PubMed ID: 2574409 [TBL] [Abstract][Full Text] [Related]
16. Clinical studies of buspirone. Schuckit MA Psychopathology; 1984; 17 Suppl 3():61-8. PubMed ID: 6150509 [TBL] [Abstract][Full Text] [Related]
17. A comparison of buspirone and placebo in relieving benzodiazepine withdrawal symptoms. Lader M; Olajide D J Clin Psychopharmacol; 1987 Feb; 7(1):11-5. PubMed ID: 2880872 [TBL] [Abstract][Full Text] [Related]
18. Buspirone. A preliminary review of its pharmacological properties and therapeutic efficacy as an anxiolytic. Goa KL; Ward A Drugs; 1986 Aug; 32(2):114-29. PubMed ID: 2874976 [TBL] [Abstract][Full Text] [Related]
20. The association of buspirone and its metabolite 1-pyrimidinylpiperazine in the remission of comorbid anxiety with depressive features and alcohol dependency. Tollefson GD; Lancaster SP; Montague-Clouse J Psychopharmacol Bull; 1991; 27(2):163-70. PubMed ID: 1924664 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]